Background. Ankle-brachial index (ABI) is a known risk factor for cardiovascular disease in general population and a reproduci- ble tool for the early detection of peripheral artery disease (PAD). Our study aim was to evaluate the ABI distribution in high CV risk patients visited by Lipid clinics and Diabetological centers in Italy and its association with other CV risk factors and patients charac- teristics. Methods. For this multicenter study, we consecutively enrolled 768 patients (F: 47.4%), with age included between 40 and 80 years old, high CV risk patients (Lipid clinics) and/or diabetics (Diabe- tological centers) at their first visit, without known PAD. Results. The 30% (N. 198) of the enrolled patients with valid meas- urement had an abnormal ABI. Lipid-lowering therapies were equally distributed among subjects with normal and abnormal ABI. Abnormal ABI was significantly more prevalent in patients in secondary prevention than in those in primary prevention (41.4% vs. 25.5%, p<0.001). ABI distribution was similar in men and wom- en, in smokers and non-smokers, hypertensives and normoten- sives, diabetics and non-diabetics. Conclusion. The main result of this multicenter transversal inves- tigation is that abnormal ABI is highly represented in high CV risk patients with or without type 2 diabetes. Further investigation are needed to understand if the implementation of ABI measurement could help to identify subjects with a worse CV risk profile, even in a high risk setting.
Abnormal ankle-brachial index in a cohort of high CV risk patients with or without type 2 diabetes: data from the multicenter RELIVE study
Bucci M;
2020-01-01
Abstract
Background. Ankle-brachial index (ABI) is a known risk factor for cardiovascular disease in general population and a reproduci- ble tool for the early detection of peripheral artery disease (PAD). Our study aim was to evaluate the ABI distribution in high CV risk patients visited by Lipid clinics and Diabetological centers in Italy and its association with other CV risk factors and patients charac- teristics. Methods. For this multicenter study, we consecutively enrolled 768 patients (F: 47.4%), with age included between 40 and 80 years old, high CV risk patients (Lipid clinics) and/or diabetics (Diabe- tological centers) at their first visit, without known PAD. Results. The 30% (N. 198) of the enrolled patients with valid meas- urement had an abnormal ABI. Lipid-lowering therapies were equally distributed among subjects with normal and abnormal ABI. Abnormal ABI was significantly more prevalent in patients in secondary prevention than in those in primary prevention (41.4% vs. 25.5%, p<0.001). ABI distribution was similar in men and wom- en, in smokers and non-smokers, hypertensives and normoten- sives, diabetics and non-diabetics. Conclusion. The main result of this multicenter transversal inves- tigation is that abnormal ABI is highly represented in high CV risk patients with or without type 2 diabetes. Further investigation are needed to understand if the implementation of ABI measurement could help to identify subjects with a worse CV risk profile, even in a high risk setting.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
